We demonstrated up-regulation of several phosphodiesterases, including PDE5, the therapeutic target of medical therapy for pulmonary hypertension, which works to inhibit PDE5, thereby increasing cGMP and vasodilation. The gene discussed is PDE5A; the disease is pulmonary arterial hypertension.